Overall (regardless of smoking Hx) Prior or current smoking Hx

Slides:

Advertisements

Similar presentations

FOUNDER, SCIENTIFIC DIRECTOR

Advertisements

Oncogenic Mutation Screening in Solitary Fibrous Tumors Elizabeth G. Demicco, Khalida Wani, Kenneth Aldape, Alexander J. Lazar, and Wei-Lien Wang.

Comparison of Mutations and Protein Expression in Potentially Actionable Targets in 5500 Triple Negative vs. non-Triple Negative Breast Cancers Joyce A.

RECURRENT CHROMOSOMAL COPY NUMBER ALTERATIONS IN CHORDOMA G. Petur Nielsen; John Iafrate; Zhenfeng Duan; Ramnik Xavier; Joseph Schwab; Andrew Rosenberg;

Molecular Testing of lung cancer in routine practice

KRAS testing in colorectal cancer

The Many Faces of Personalized Health Care: Pediatric and Medical Oncology Joshua D. Schiffman, MD Edward B. Clark, MD Chair in Pediatric Research Associate.

1 Research Data Marts In Support Of Cancer Personalized Medicine Jack London, PhD and Devjani Chatterjee, PhD Jefferson Kimmel Cancer Center, Philadelphia.

1 Jack London, PhD Research Professor, Cancer Biology Thomas Jefferson University Informatics Shared Resource Director Sidney Kimmel Cancer Center at Jefferson.

Exome sequencing analysis of the mutational spectrum in carcinogen and genetic models of Kras-driven lung cancer Peter Westcott, Kyle Halliwill, Minh To,

Molecular Biology of Cancer. CANCER TAKES TIME CANCER IS A DISEASE OF GENETIC MUTATIONS ACCUMULATION OF MANY MUTATIONS CAUSES CANCER.

Supplementary Fig. S1 A.B.. A. Supplementary Fig. S2 B. C.

HIGH-THROUGHPUT MUTATION PROFILING OF OSTEOSARCOMA PRIMARY TUMORS AND CELL LINES IDENTIFIES NEW MUTATIONS IN PREVIOUSLY UNASSOCIATED ONCOGENES AND TUMOR.

NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131)

A novel 3D human tissue culture model

Evaristo Maiello U.O.C. Oncologia IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo (FG) Napoli, 16 ottobre 2015.

Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.

Module 4: How do unrealistic expectations confound the results of our analyses Case Studies in Bioinformatics Giovanni Ciriello

Evidence-guided tumor profiling to individualize therapy decisions.

NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) A phase II precision medicine cancer trial Co-developed by the ECOG-ACRIN Cancer Research.

NCI-Molecular Analysis for Therapy Choice (NCI-MATCH EAY131)

Research discoveries to diagnostic panels – an update Darren D. O’Rielly, Ph.D., FCCMG Director, Molecular Genetics Laboratory, Eastern Health Director,

Date of download: 7/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Follicular Variant of Papillary Thyroid Cancer: Encapsulated,

The Center for Personalized Diagnostics: Past, Present, and FUTURE

Canadian Bioinformatics Workshops

New genetic cancer tests

Cancer Precision Medicine: A Primer

Diane Reidy-Lagunes, MD and Nitya Raj, MD

CCO Independent Conference Highlights

Advances in Molecular Biology of Lung Disease

Potential actionable targets in appendiceal cancer detected by immunohistochemistry (IHC), fluorescent in situ hybridization (FISH) and mutational analysis.

A B C D Reference Standard (HD728)

Incorporating Genomics into Clinical Care

Surgical Resection Of Residual Breast Cancer: Stem Cells that Neoadjuvant Chemotherapy Leave Behind SuEllen Pommier, Ph.D., Cynthia Jackson, M.S., Jennifer.

Christopher S. Lathan, M. D. , M. S. , M. P. H

Impact of Reimbursement Decisions on Innovation in Genetic Testing

UCSF 500 Cancer Gene Panel (538 genes, 40 with intronic regions)

Figure S1, FGFR2 copy gain and overexpression in H716 cells A

Clinical Trial Available

Yes, Patient #1 Yes, Patient #3 EGFR sequencing chromatograms

Summary of genetic alterations in resistant biopsies among patients progressing on ceritinib or alectinib. Summary of genetic alterations in resistant.

Example of next generation sequencing (NGS) raw data-BRAF V600E mutation in melanoma. Example of next generation sequencing (NGS) raw data-BRAF V600E mutation.

11/29/ /29/2018 Dr Zeinalian.

Example of next generation sequencing (NGS) raw data-BRAF V600E mutation in melanoma. Example of next generation sequencing (NGS) raw data-BRAF V600E mutation.

NCI-Molecular Analysis for Therapy Choice (NCI-MATCH / EAY131)

Supplemental Figure S1 B A C D.

Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid Meenakshi Mehrotra, Rajesh.

黃其晟1 塗昭江1 張景年1 黃清水2 1天主教輔仁大學附設醫院乳房外科 2國泰綜合醫院外科部

Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer Alexa B. Schrock, PhD, Allison.

Pertinent Germline Findings

Progress of the NSCLC Revolution

Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid Meenakshi Mehrotra, Rajesh.

Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics Maksym.

Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers Carla Verri, MSc, Cristina Borzi, MSc, Todd Holscher,

Cancer WGS Analytical Pipeline Validation

Matthias Scheffler, MD, Michaela A

Abemaciclib (µM) LY (µM)

Supplementary Figure 1 A B C CD56 D E F CD56.

Raymond N. DuBois, M.D., Ph.D. Executive Director

Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related Genes Rajesh R. Singh, Keyur P. Patel, Mark J.

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

TS Tumor Panel (15 Genes) Overview

Ernest Nadal, MD, Guoan Chen, MD, PhD, John R

Volume 156, Issue 8, Pages e4 (June 2019)

Esteller, New England Journal of Medicine, 2008

Supplementary Figure 3 Sequential Branch-off De novo * * * * **

Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma Filippo Lococo, MD,

Biology of Cancer and Omics

Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.

Presentation transcript:

Overall (regardless of smoking Hx) Prior or current smoking Hx NGS or Sanger sequencing Overall (regardless of smoking Hx) Nonsmoking Hx Prior or current smoking Hx Biomarker Positive Total Percent ABL1 1 175 0.6 12 0.0 8 AKT1 185 0.5 ALK 186 APC 4.3 8.3 12.5 ATM 5 182 2.7 BRAF 3 274 1.1 13 CDH1 4 2.2 KIT (cKIT) 235 0.4 10 MET (cMET) 6 3.2 CSF1R CTNNB1 2 EGFR 193 1.6 ERBB2 ERBB4 FRXW7 FGFR1 FGFR2 FLT3 GNA11 161 7 GNAQ 115 GNAS HNF1A 159 11 HRAS 157 IDH1 JAK2 JAK3 KDR KRAS 292 4.5 MLH1 MPL NOTCH1 184 NPM1 NRAS 227 PDGFRA 181 PIK3CA 56 261 21.5 14 42.9 9 11.1 PTEN 179 3.4 PTPN11 RB1 RET SMAD4 SMARCB1 SMO 166 STK11 TP53 97 52.7 50.0 62.5 VHL 174 Supplementary table 2: Sanger or NGS data for bladder cancer patients